نتائج البحث

Assessment of risk factors for virological nonsuppression following switch to dolutegravir and lamivudine, or bictegravir, emtricitabine, and tenofovir alafenamide fumarate in a real-world cohort of treatment-experienced adults living with HIV.

• Authors : Lee SY; Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan City, Taiwan.; Lin YC

Subjects: HIV Infections*/HIV Infections*/HIV Infections*/drug therapy ; HIV Infections*/HIV Infections*/HIV Infections*/virology ; Pyridones*/Pyridones*/Pyridones*/therapeutic use

• Source: PloS one [PLoS One] 2024 Nov 20; Vol. 19 (11), pp. e0314003. Date of Electronic Publication: 2024 Nov 20 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ /lamivudine /dolutegravir (TLD) roll-out in Mozambique.

• Authors : Ismael N; Instituto Nacional de Saúde, EN1, Bairro da Vila - Parcela N˚3943, Marracuene Sede, Marracuene, Maputo Province, Mozambique. .; Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. .

Subjects: HIV Infections*/HIV Infections*/HIV Infections*/drug therapy ; HIV Infections*/HIV Infections*/HIV Infections*/virology ; Drug Resistance, Viral*/Drug Resistance, Viral*/Drug Resistance, Viral*/genetics

• Source: BMC infectious diseases [BMC Infect Dis] 2024 Jul 29; Vol. 24 (1), pp. 748. Date of Electronic Publication: 2024 Jul 29.Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334

تفاصيل العنوان

Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia.

• Authors : Luwaya EL; School of Medicine and Health Sciences, Mulungushi University, Livingstone, Zambia.; Mwape L

Subjects: HIV-1*/HIV-1*/HIV-1*/genetics ; HIV-1*/HIV-1*/HIV-1*/drug effects ; HIV Infections*/HIV Infections*/HIV Infections*/drug therapy

• Source: PloS one [PLoS One] 2024 Sep 06; Vol. 19 (9), pp. e0308869. Date of Electronic Publication: 2024 Sep 06 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe.

• Authors : Kouamou V; Unit of Internal Medicine, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare P.O. Box A178, Zimbabwe.; Biomedical Research and Training Institute, Harare P.O. Box A178, Zimbabwe.

Subjects: Lamivudine*/Lamivudine*/Lamivudine*/pharmacology ; Lamivudine*/Lamivudine*/Lamivudine*/therapeutic use; Adult

• Source: Viruses [Viruses] 2023 Sep 05; Vol. 15 (9). Date of Electronic Publication: 2023 Sep 05.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915

تفاصيل العنوان

Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021) (DRIVE-AHEAD)

• Source: A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in

تفاصيل العنوان

Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (DRIVE-SHIFT)

• Source: A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and

تفاصيل العنوان

Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States.

• Authors : Pierone G; Whole Family Health Center, Vero Beach, FL, USA.; Fusco JS

Subjects: Pyridones*/Pyridones*/Pyridones*/therapeutic use ; Heterocyclic Compounds, 3-Ring*/Heterocyclic Compounds, 3-Ring*/Heterocyclic Compounds, 3-Ring*/therapeutic use ; Heterocyclic Compounds, 3-Ring*/Heterocyclic Compounds, 3-Ring*/Heterocyclic Compounds, 3-Ring*/administration & dosage

• Source: AIDS research and therapy [AIDS Res Ther] 2024 Oct 26; Vol. 21 (1), pp. 76. Date of Electronic Publication: 2024 Oct 26.Publisher: BioMed Central Country of Publication: England NLM ID: 101237921 Publication Model: Electronic Cited Medium: Internet ISSN: 1742-6405

تفاصيل العنوان

Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide

• Authors : National Institute of Allergy and Infectious Diseases (NIAID)

• Source: Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)

تفاصيل العنوان

Comparison of patients using lamivudine, entecavir, and tenofovir according to liver fibrosis markers fibrosis-4 and aspartate aminotransferase-to-platelet ratio index scores.

• Authors : Okan HD; Department of Infectious Diseases and Clinic Microbiology, Sakarya University, Faculty of Medicine, Sakarya, Turkey.; Karabay O

Subjects: Lamivudine*/Lamivudine*/Lamivudine*/therapeutic use ; Hepatitis B, Chronic*/Hepatitis B, Chronic*/Hepatitis B, Chronic*/drug therapy; Humans

• Source: Indian journal of pharmacology [Indian J Pharmacol] 2023 Jan-Feb; Vol. 55 (1), pp. 14-20.Publisher: Medknow Publications Country of Publication: India NLM ID: 7902477 Publication Model: Print Cited Medium: Internet ISSN: 1998-3751

تفاصيل العنوان

The risk of dyslipidemia on PLHIV associated with different antiretroviral regimens in Huzhou.

• Authors : Wang Y; Huzhou Center for Disease Control and Prevention, Huzhou, Zhejiang, China.; Division of Epidemiology and Health Statistics, Department of Preventive Medicine, School of Public Health & Management, Wenzhou Medical University, Wenzhou, Zhejiang, China.

Subjects: Dyslipidemias*/Dyslipidemias*/Dyslipidemias*/epidemiology ; Dyslipidemias*/Dyslipidemias*/Dyslipidemias*/chemically induced ; HIV Infections*/HIV Infections*/HIV Infections*/drug therapy

• Source: PloS one [PLoS One] 2024 Sep 20; Vol. 19 (9), pp. e0305461. Date of Electronic Publication: 2024 Sep 20 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان